vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased to announce that enrolment into the pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial is completed. vasopharm remains on track to deliver headline data by end of 2020.
Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD2 study evaluating the safety and efficacy of ruxolitinib cream in adolescent and adult patients (age ≥ 12 years) with atopic dermatitis (AD).
Acceleron Pharma said that the PULSAR Phase 2 trial of sotatercept met its primary and key secondary endpoints in patients with pulmonary arterial hypertension (PAH).
Daiichi Sankyo and AstraZeneca said that the HER2 directed antibody drug conjugate (ADC) DS-8201 has met the primary endpoint in the phase 2 DESTINY-Gastric01 trial.
Lexicon Pharmaceuticals announced real-world data on XERMELO’s (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American Society for Clinical Oncology (ASCO) 2020 Symposium.
Roche’s Tecentriq (atezolizumab) has failed to meet its primary endpoint in phase III muscle-invasive urothelial cancer (MIUC) trail.
LB Pharmaceuticals, Inc., (“LB”, or the “Company”) a biotechnology company focused on developing novel and improved versions of successful CNS treatments, announced today the administration of the first dose of LB-102 in a Phase 1 clinical trial.
Roche announced that its risdiplam has achieved primary endpoint in the FIREFISH study in infants with type 1 spinal muscular atrophy.
Verrica Pharmaceuticals announced the presentation of positive data from a post-hoc pooled analysis of the pivotal Phase 3 CAMP trials evaluating the safety and efficacy of VP-102 (cantharidin 0.7% topical solution), Verrica’s lead product candidate for the treatment of molluscum contagiosum (molluscum).
Innovation Pharmaceuticals, a clinical stage pharmaceutical company, announced that the company has received agreement from the study’s Dose Escalation Committee (DEC) to progress dosing to the second cohort in its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.